Order Article Reprints

Lu ER, Hoo CPL, Cheung HM, Wong IWC, Fung KFK, Chang SLY, Lee ACW, Fu ECH, Ku DTL, Yau JPW, et al. End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers. 2026; 18(6):1028. https://doi.org/10.3390/cancers18061028

Lu, Evelyn R., Calvin P. L. Hoo, Ho Ming Cheung, I. W. C. Wong, K. F. Kevin Fung, Sylvia L. Y. Chang, Anselm C. W. Lee, Eric C. H. Fu, Dennis T. L. Ku, Jeffrey P. W. Yau, and et al. 2026. "End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta" Cancers 18, no. 6: 1028. https://doi.org/10.3390/cancers18061028

Lu, E. R., Hoo, C. P. L., Cheung, H. M., Wong, I. W. C., Fung, K. F. K., Chang, S. L. Y., Lee, A. C. W., Fu, E. C. H., Ku, D. T. L., Yau, J. P. W., Shing, M. M. K., Mak, C. Y. K., Liu, A. P. Y., & Chan, G. C. F. (2026). End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy—Modified N7 Regimen with Dinutuximab Beta. Cancers, 18(6), 1028. https://doi.org/10.3390/cancers18061028